Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-230-0 | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No experimental toxicokinetic study is available on 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate.
However, as per REACH guidance document R7.C , information on absorption, distribution, metabolism and excretion may be deduced from the physical-chemical properties and QSAR predictions.
Based on the physical-chemical properties and QSAR predictions, the absorption of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate is expected to be high by oral route and inhalation, low by dermal route. A good distribution and excretion of the substance are expected.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 10
- Absorption rate - inhalation (%):
- 100
Additional information
No experimental toxicokinetic study is available on 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate. However, as per REACH guidance document R7.C, information on absorption, distribution, metabolism and excretion may be deduced from the physical-chemical properties, including:
-Mean molecular weight: 218 g/mol
-Water solubility: 86 mg/L
-Partition coefficient Log Kow: 2.5
-Vapour pressure: 0.000288 Pa (25°C)
ABSORPTION
Oral absorption: The moderate values of log Kow (2-4), the moderate solubility and the moderate molecular weight (below 500 g/mol) of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate are favorable for an oral absorption. The oral absorption is confirmed in the acute toxicity study, in which severe clinical signs and mortality were observed at 2000 mg/kg bw. The worst case value (100%) is used as oral absorption for the risk assessment.
Dermal absorption: With a high solubility of 86 g/L and a moderate log Kow, dermal absorption is anticipated to be moderate to high. According to the IH skin perm (QSAR), the dermal absorption of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate is very low (<10 %). The substance showed allergic reaction in the LLNA: it is evidence that some uptake must have occurred although it may only have been a small fraction of the applied dose. For the risk assessment, 10% of dermal absorption is taken into account.
Inhalation absorption: Based on the low value of the vapour pressure (< 0.001 Pa), 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate is considered as a low volatile substance.For the risk assessment, 100% of inhalation absorption is taken into account.
DISTRIBUTION and METABOLISM
No specific data is available on the distribution or metabolism of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate.
ELIMINATION
Due to the moderate molecular weight (< 300), the moderate water solubility and the moderate log kow, the excretion of 1,4-butanediylbis[oxy(2-hydroxy-3,1-propanediyl)] diacrylate in the urines is expected.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
